NCT03972501View on ClinicalTrials.gov

An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

December 11, 2020

Study Completion Date

December 11, 2020

Conditions
Meibomian Gland Dysfunction (MGD)Contact Lens Discomfort (CLD)
Interventions
DRUG

AZR-MD-001 Vehicle

AZR-MD-001 is an ophthalmic ointment

DRUG

AZR-MD-001 Active Dose

AZR-MD-001 is an ophthalmic ointment

Trial Locations (1)

2052

School of Optometry and Vision Science, University of New South Wales, Sydney

Sponsors

Lead Sponsor

Azura Ophthalmics
All Listed Sponsors
collaborator

The University of New South Wales

OTHER

lead

Azura Ophthalmics

INDUSTRY

NCT03972501 - An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD) | Biotech Hunter | Biotech Hunter